<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234038</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 183750-CS4</org_study_id>
    <nct_id>NCT01234038</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel</brief_title>
  <acronym>NSCLC</acronym>
  <official_title>A Phase 1b/2 Study of Carboplatin-Paclitaxel, With or Without ISIS 183750 (an eIF4E Inhibitor), in Patients With Stage IV Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the overall survival of patients with Stage IV
      non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin
      and paclitaxel.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>At the end of each 21 day cycle</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS EIF4E Rx</intervention_name>
    <description>800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle</description>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS EIF4E Rx</intervention_name>
    <description>1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle</description>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS EIF4E Rx</intervention_name>
    <description>(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle</description>
    <arm_group_label>Part 2 Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle</description>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_label>Part 2 Arm A</arm_group_label>
    <arm_group_label>Part 2 Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle</description>
    <arm_group_label>Part 1 Cohort 1</arm_group_label>
    <arm_group_label>Part 1 Cohort 2</arm_group_label>
    <arm_group_label>Part 2 Arm A</arm_group_label>
    <arm_group_label>Part 2 Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients age &gt;/= 18 years

          -  Histologically or cytologically confirmed diagnosis of NSCLC

          -  Stage IV disease (including patients with pleural effusion who were previously
             classified as Stage IIIB)

          -  All of the following if patient has had prior radiation therapy:

               1. Lesion(s) used for determination of response were not previously irradiated or
                  have increased in size since the completion of radiotherapy

               2. The patient has recovered from any acute effects of the radiotherapy

               3. Radiotherapy was completed at least 4 weeks prior to Screening

          -  Part 1: Have at least non-measurable evaluable disease (e.g., lesions which are
             smaller than the minimum size required for measurability; other non-measurable lesions
             such as bone metastases, malignant pleural effusion)

          -  Part 2: Have measurable disease, defined as at least 1 lesion that can be accurately
             measured in at least 1 dimension

          -  Performance status of 0 or 1 on the ECOG Performance Status Scale

          -  Have an estimated life expectancy of at least 12 weeks

          -  Adequate organ function within 14 days prior to first study dose (ISIS EIF4E Rx or
             carboplatin/paclitaxel, whichever occurs first) as defined by:

               1. Absolute neutrophil count (ANC) &gt;/= 1.5 x 109/L

               2. Platelet count &gt;/= 100 x 109/L

               3. Hemoglobin &gt;/=9 g/dL (&gt;/= 5.6 mmol/L). Patients may receive packed RBC
                  transfusion to achieve this level at the discretion of the investigator.

               4. Total bilirubin &lt; 1.5 x upper limit of normal (ULN) unless elevated secondary to
                  conditions such as Gilbert's Disease

               5. Aspartate aminotransferase (AST) &lt; 3 x ULN (&lt; 5 x ULN in the presence of hepatic
                  metastases)

               6. Alanine aminotransferase (ALT) &lt; 3 x ULN (&lt; 5 x ULN in the presence of hepatic
                  metastases)

               7. Alkaline phosphatase &lt; 3.0 x ULN

               8. Calculated creatinine clearance &gt;/= 60 mL/min per Cockcroft and Gault formula

          -  Satisfy one of the following:

               1. Females: non-pregnant and non-lactating; surgically sterile, post-menopausal, or
                  patient or partner compliant with a reliable contraceptive regimen, as determined
                  by Investigator, for 4 weeks prior to Screening. Patients of reproductive
                  potential must test negative for pregnancy at Screen and must agree to use a
                  reliable method of birth control during the study and for the 10 weeks following
                  the last dose of ISIS EIF4E Rx.

               2. Males: surgically sterile or patient or partner must agree to use a reliable
                  contraceptive method, as determined by the Investigator during the study and for
                  the 10 weeks following the last dose of ISIS EIF4E Rx.

          -  For Part 1: have discontinued all prior chemotherapies, biological therapies, and
             other investigational therapies for cancer for at least 4 weeks (6 weeks for
             mitomycin-C or nitrosoureas) prior to study treatment and recovered from the acute
             effects of therapy.

        Exclusion Criteria:

          -  Part 1: More than 2 prior chemotherapy or biological therapy regimens (approved or
             experimental) for NSCLC, not counting adjuvant and neoadjuvant treatment. A regimen is
             defined as two or more consecutive cycles of treatment.

          -  Part 2: Any prior chemotherapy or biological therapy (approved or experimental) for
             NSCLC including adjuvant and neoadjuvant treatments

          -  Treatment with another investigational drug, biological agent, or device within 4
             weeks (6 weeks for biological agents) before Screening or 5 half-lives of study agent,
             whichever is longer

          -  Patients with treated or untreated parenchymal brain metastases or leptomeningeal
             disease. Brain imaging is required for symptomatic patients to rule out brain
             metastases, but is not required in asymptomatic patients.

          -  Patients with known pericardial effusion

          -  Have active infection or serious concomitant systemic disorder (for example, heart
             failure) incompatible with the study (at the discretion of the Investigator)

          -  Presence or history of malignancy other than NSCLC, carcinoma in situ of the cervix,
             or non-melanoma skin cancer. In the case of other malignancies, patients may be
             considered for participation if the prior malignancies were diagnosed and definitively
             treated at least five years previously with no subsequent evidence of recurrence.

          -  Presence of an underlying disease state associated with active bleeding

          -  Ongoing therapy with oral or parenteral anticoagulants (e.g., heparin,
             warfarin/coumadin). Low-dose anticoagulants for maintenance of catheter patency and
             low dose aspirin (â‰¤ 325 mg/day) and nonsteroidal anti-inflammatory agents are not
             exclusionary.

          -  Concurrent treatment with other anticancer drugs

          -  Pre-existing peripheral neuropathy &gt;/=Common Terminology Criteria for Adverse Events
             Version 4.0 (CTCAE) Grade 2

          -  Known history of HIV, HCV, or chronic HBV infection

          -  Previous treatment with a therapeutic antisense oligonucleotide or siRNA

          -  Planned concomitant participation in another clinical trial of an experimental agent,
             vaccine, or device

          -  Have any other medical conditions that in the opinion of the Investigator, would make
             the patient unsuitable for enrollment, or could interfere with the patient
             participating in or completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Achieve Clinical Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Cancer Center</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Little Rock Cancer Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville - James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koranyi National Institute of TBC and Pulmonology</name>
      <address>
        <city>Budapest</city>
        <zip>H-1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Faculty of Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>H-1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Medical and Health Science Center</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Thoracic Diseases of Csongrad County Local Governmental</name>
      <address>
        <city>Deszk</city>
        <zip>H-6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes Country Pandy Kalman Hospital</name>
      <address>
        <city>Gyula</city>
        <zip>H-5703</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Dluski Provincial Specialist Hospital</name>
      <address>
        <city>Bialystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Public Teaching Hospital No. 4 In Lublin</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idependent Public Tuberculosis an Lung Diseases Facilities</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-357</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialist Tuberculosis and Lung Diseases Hospitals</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-241</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alojzy Pawelec Provincial Hospital of Lung Diseases</name>
      <address>
        <city>Wodzislaw Slaski</city>
        <zip>44-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Institution: Arkhangelsk Regional Clinical Oncology Center, Chemotherapy department</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Therapeutical and Prophylactic Institution: Chelyabinsk Regional Clinical Oncology Center, Chemotherapy Department</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Healthcare Institution: Sverdlovsk Regional Oncology Center, Radiotherapy Department</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution: Ivanovo Regional Oncology Center, Chemotherapy Department</name>
      <address>
        <city>Ivanovo</city>
        <zip>153013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-State Medical Institution: Central Clinical Hospital #2 n.a. N.A. Semashko under OJSC Russian Railways, Chemotherapy Dept.</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution: Leningrad Regional Clinical Hospital, Thoracic Surgery Department</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Healthcare Institution: &quot;City Clinical Oncology Center&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Higher Educational Institution: St. Petersburg State Medica University n.a.I.P. Pavlov under the Federal Agency for Healthcare and Social Development, Pulmonology Research Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution: Samara Regional Clinical Oncology Center, Chemotherapy Department</name>
      <address>
        <city>Samara</city>
        <zip>443031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <last_update_submitted>November 1, 2012</last_update_submitted>
  <last_update_submitted_qc>November 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

